PATENT CLAIM ANALYSIS

Application Number: 16423992
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["514", "236200"]

Abstract:
The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

Claim (Index 54):
The method according to  claim 48 , wherein the disease, disorder, syndrome or condition is cancer.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 100.0
- Lexical Diversity: 1.43137
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15228681', '14745204', '14123409', '15919460', '15534105']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7659622485576378
- 35 USC 102 Novelty (BERT): 0.5498168577933616
- Combined Prediction Score: 0.7443477094812102
- Mean Citation Score: 378.88254799999993
- Max Citation Score: 426.93008
- Similarity Product: 222.53405105350487

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test